从实验室到公司,哈佛抗生素成果转化引关注

2015-03-05 佚名 生物谷

最近,一家新成立不久的抗生素医药公司Macrolide Pharmaceuticals宣布公司已经完成了总额达2200万美元的首轮融资。可千万不要小看这家名不见经传的小公司,它是由哈佛大学著名的化学家Andrew Myers创办的,可谓是出身名门。这家公司刚刚成立就吸引了包括诺华风投、罗氏风投和SROne(葛兰素史克旗下风投公司)的高度注意。而此次Macrolide Pharmaceuti

最近,一家新成立不久的抗生素医药公司Macrolide Pharmaceuticals宣布公司已经完成了总额达2200万美元的首轮融资。可千万不要小看这家名不见经传的小公司,它是由哈佛大学著名的化学家Andrew Myers创办的,可谓是出身名门。这家公司刚刚成立就吸引了包括诺华风投、罗氏风投和SROne(葛兰素史克旗下风投公司)的高度注意。而此次Macrolide Pharmaceuticals的首轮投资就由这三家风投公司领衔。

Andrew Myers创办的Macrolide Pharmaceuticals的杀手锏就在于大环内酯类抗生素药物的研发。大环内酯类物质能够通过与细菌的核糖体结合而阻断细菌蛋白质的合成。这一原理能够用于开发新型抗生素药物。然而,由于人类一直无法找到有效的方法合成大环内酯类物质,这一有前景的工作就只能停留在实验室之中。Andrew Myers表示,他们现在已经找到了一种稳定可靠的方法合成这种物质。利用这种新技术,Andrew Myers等人已经获得了超过200种大环内酯类物质。可以想见,这对于抗生素药物研发产业来说具有重要意义。

值得注意的是,这并不是Andrew Myers的首次创业,2006年他就和另外一名科学家Lawrence Miller创办了一家抗生素药物公司--Tetraphase Pharmaceuticals。不久前Tetraphase Pharmaceuticals已经成功完成了一项新型四环素药物的临床三期研究。

诚然,对于无比庞大的生物与医药产业,Macrolide Pharmaceuticals只能算是个小不点,而2亿2千万美元的融资额也只不过是每年生物医药产业投资的零头。但是真正值得我们关注的是国外生物医药产业产学转化的高效通道。科学家们能够快速将其成果转化为生产力,而市场则对这种成果转化保持着高度敏感。

近年来,随着国外技术人才纷纷来到中国创业,中国生物医药的成果转化相较于以前已经大大加快。但是,怎样才能构建一条从研究到产业顺畅的转化渠道,才是摆在政府、企业、学术机构乃至市场面前的一个重要课题。

详细英文报道:

Harvard chemistry professor Andrew Myers says he's made a breakthrough that can greatly expand a class ofantibiotics, forming the foundation for his latest startup: Macrolide Pharmaceuticals. And the biotech is launching today with $22 million in venture cash from an impressive group of venture backers, with three Big Pharmas in the VC mix and some early shots at a possible early-stage marquee deal.

Once again, Myers has teamed up with Lawrence Miller for the startup. Back in 2006 the two also launched Tetraphase Pharmaceuticals ($TTPH), an antibacterial company that's been working with a tetracycline platform and recently heralded the success of a Phase III study.

Novartis Venture Fund, Gurnet Point Capital, Roche Ventures, and SROne (GlaxoSmithKline) all came in on the A round after Harvard's tech office struck a deal to outlicense the technology, the latest in a flurry of pacts that has focused fresh attention on developing antibiotics.

Macrolides are a class of antibiotics which bind to ribosomes in bacteria, inhibiting bacterial protein synthesis and stopping an attack. But unable to synthesize most macrolides, researchers have been limited in developing them. Myers, though, says he's found the key to developing a full pipeline of them.

Myers' breakthrough in synthesizing macrolides--constructing them out of "basic industrial chemicals," says Miller--leaves the company at an early stage of development with a two- to three-year march to the clinic. But Miller adds that Myers has already synthesized more than 200 macrolides, and with three Big Pharma venture groups behind them, they've already been approached by a couple of large pharmas interested in striking a preclinical collaboration.

"We're pleased by who's shown interest," says Miller. Now the CEO says the company will take the next two or three months to evaluate whether they should go ahead and strike a collaboration deal now or wait until they have more information about how this expanded class of antibiotics works. In the meantime, Miller says he's also hiring as fast as he can, building a team around the three staffers currently on board.

The Big Pharma interest in the A round underscores a resurgence in the field. As Miller notes, when he and Myers started Tetraphase in 2006, there was little industry interest in antibiotics, which had been largely marginalized. Now, though, Roche ($RHHBY) and others have been keen to grow in the field, seeing fresh prospects as the U.S. adds fresh incentives for developers.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1689876, encodeId=c96816898e613, content=<a href='/topic/show?id=a6fd540305d' target=_blank style='color:#2F92EE;'>#成果转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54030, encryptionId=a6fd540305d, topicName=成果转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b5828899049, createdName=ms6323715314570549, createdTime=Mon Jun 29 14:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557414, encodeId=d7f9155e4149c, content=<a href='/topic/show?id=7bec398e2e6' target=_blank style='color:#2F92EE;'>#哈佛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39872, encryptionId=7bec398e2e6, topicName=哈佛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c7014916331, createdName=amyloid, createdTime=Sat Mar 07 04:03:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17696, encodeId=dd381e696ff, content=加快转化速度,有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Mar 05 15:02:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1689876, encodeId=c96816898e613, content=<a href='/topic/show?id=a6fd540305d' target=_blank style='color:#2F92EE;'>#成果转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54030, encryptionId=a6fd540305d, topicName=成果转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b5828899049, createdName=ms6323715314570549, createdTime=Mon Jun 29 14:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557414, encodeId=d7f9155e4149c, content=<a href='/topic/show?id=7bec398e2e6' target=_blank style='color:#2F92EE;'>#哈佛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39872, encryptionId=7bec398e2e6, topicName=哈佛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c7014916331, createdName=amyloid, createdTime=Sat Mar 07 04:03:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17696, encodeId=dd381e696ff, content=加快转化速度,有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Mar 05 15:02:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-07 amyloid
  3. [GetPortalCommentsPageByObjectIdResponse(id=1689876, encodeId=c96816898e613, content=<a href='/topic/show?id=a6fd540305d' target=_blank style='color:#2F92EE;'>#成果转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54030, encryptionId=a6fd540305d, topicName=成果转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b5828899049, createdName=ms6323715314570549, createdTime=Mon Jun 29 14:03:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557414, encodeId=d7f9155e4149c, content=<a href='/topic/show?id=7bec398e2e6' target=_blank style='color:#2F92EE;'>#哈佛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39872, encryptionId=7bec398e2e6, topicName=哈佛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c7014916331, createdName=amyloid, createdTime=Sat Mar 07 04:03:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17696, encodeId=dd381e696ff, content=加快转化速度,有可能的, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Mar 05 15:02:00 CST 2015, time=2015-03-05, status=1, ipAttribution=)]
    2015-03-05 lovetcm

    加快转化速度,有可能的

    0

相关资讯

CMAJ:心脏病患者慎吃抗生素

口服红霉素与安体舒通(一种利尿剂,用于治疗心脏衰竭)联合用药会加倍老年患者猝死的风险。最近一份来自加拿大的研究报告得出此结论。 由加拿大多伦多圣迈克尔医院的Tony Antoniou博士领导的团队分析了66岁以上的患者从1994年到2011年使用安体舒通治疗的检测结果。该研究囊括的患者数量超过20万,其中1万多名患者出现了猝死,另外有349名患者在服用抗生素之后的14天内病逝。 

抗生素还是抗癌药?Pharmacyclics温馨提示

【新闻事件】:今天只有布鲁顿酶抑制剂Ibrutinib一个产品的Pharmacyclics宣布将插上草标出售自己,标价170-180亿美元。Ibrutinib去年这个时候上市,已经有四个批准适应症,去年销售为约5亿美元。今年估计能有超过10亿美元的销售,到2018年可达40亿美元。现在Pharmacyclics的市值是150亿美元。其合作伙伴强生和抗癌大佬诺华据说是潜在买主。 【药源解析】:

决默沙东Zerbaxa,阿特维斯新型 产品Avycaz喜获FDA批准

全球仿制药巨头阿特维斯(Actavis)近日宣布,新型抗生素产品Avycaz获得FDA批准,用于复杂性腹腔内感染 (cIAI)(联合甲硝唑)及复杂性尿路感染 (cUTI) 的治疗。此前,FDA已授予Avycaz合格传染病产品 (QIDP)资格,并根据II期临床数据进行了优先审查,因此Avycaz应保守用于有限或无替代治疗方案的患者群体。该药的III期临床正在进行中,相关数据将用于支持Avyca

Ann Surg:预测严重烧伤病人被感染风险 降低抗生素使用

马萨诸塞州总医院(MGH)的研究人员领导的一个科研小组找到了一系列可以预测哪个烧伤病人最有被多次感染的风险的特征。这些特征包括病人不同的基因表达水平。在感染发生之前预测被感染的风险,可以指导哪些病人需要接受预防性治疗,并减少对风险较低的病人使用不必要的抗生素。" 使用临床和基因组的因素来预测哪些病人有被多次感染的风险,可以改善治疗效果,减少抗生素抗性。 马萨诸塞州总医院的研究人员领导的一

Nature:关于抗生素的一条好消息

耐受常用药物治疗的感染日渐增多,却缺乏新型抗生素来替代那些不再有效的药物,这已成为全球亟待解决的问题。一种生产抗生素的特殊方法或可对此有所助益。用来寻找teixobactin的iChip研究人员在周三的《自然》(Nature)杂志上报道,这种从生活在泥土里的细菌中提取药物的方法生产出了一种新的强力抗生素。在小鼠试验中,这种新药——teixobactin可以轻松治愈严重感染,且没有出现副作用。更

PNAS:抗生素促进细菌的菌膜生成的机制

许多人都把服用抗生素作为治疗细菌感染的方法。而来自北卡罗来纳大学教堂山分校研究者们认为这一观点需要做一些修改了。 由该校微生物与免疫系的Elizabeth Shank博士以及药学系的研究生Rachel Bleich主导完成的这项研究不仅为我们治疗细菌感染提供了新的思路,而且从根源上改变了我们对微生物分泌抗生素的原因的理解。   "很长时间内我们所认为的细菌分泌抗生素的原因是杀死其它